Navigation Links
Experimental Drug May Cut Severe Asthma Attacks: Study

By Steven Reinberg
HealthDay Reporter

THURSDAY, Aug. 16 (HealthDay News) -- An experimental drug known as mepolizumab may reduce outbreaks by almost 50 percent in people with a type of hard-to-treat asthma, an early study finds.

About a third of people with severe asthma have what is called eosinophilic asthma, in which inflammatory cells called eosinophils cause swelling of lung airways. Standard asthma treatment with inhaled steroids isn't effective, so these patients take oral steroids, which have many side effects, the researchers explained.

Mepolizumab blocks the production of eosinophils and reduces the frequency of severe asthma outbreaks, which may reduce the need for steroids, the researchers said.

The new drug is a monoclonal antibody, a class of drugs involving naturally occurring human antibodies that are genetically altered in a laboratory, cloned in large numbers and introduced into the patient to target disease sites.

"This is a promising new drug treatment," said lead researcher Dr. Ian Pavord, a consultant physician at the University Hospitals of Leicester NHS Trust, in England. "I think it's going to become a viable treatment and it offers hope to a group of people that are having really big problems with their asthma."

The purpose of this trial was to find out the best dose of the drug and to identify the type of patients most likely to benefit from it, Pavord said.

"It's been a successful study, because we have established the drug is effective even in low doses and patients can be identified through a blood test," Pavord said.

Some patients taking mepolizumab may be able to reduce the amount of steroids they take, Pavord said.

"If that were the case it would be very attractive to the patient," he said.

GlaxoSmithKline, the maker of mepolizumab, funded the trial. The findings were published Aug. 16 in the online edition of the journal The Lancet.

For the study, Pavord's team randomly assigned more than 600 patients with severe asthma to receive one of three doses of mepolizumab or a placebo. The drug is given intravenously once a month. Participants included asthma patients from 81 medical centers in 13 countries, and their ages ranged from 12 to 74 years old.

After a year, the researchers found that patients taking mepolizumab had about half the number of severe outbreaks requiring ER visits or hospitalizations as patients taking a placebo. Patients taking mepolizumab also had half as many outbreaks that required oral steroids.

Although mepolizumab effectively reduced outbreaks, it didn't produce consistent improvements in symptoms or lung function, the study found. "It's not a cure," Pavord said. "It's likely to be a long-term treatment."

Headaches and swelling of the nasal passages were seen among patients taking the drug and those on placebo, the researchers noted. Side effects from oral steroids include mood changes, increased appetite, weight gain and acne.

Although three patients died during the study, their deaths were deemed to be unrelated to the treatment.

Since the drug is still experimental and phase 3 trials are just getting under way, the potential cost of the drug, if approved, isn't known. Approval of mepolizumab for asthma isn't expected for at least three to four years, Pavord said.

"The results of this study are very impressive," said Dr. Rubin Cohen, director of the Asthma Center at North Shore-LIJ Health System in New Hyde Park, N.Y.

He said the drug could be very helpful for patients with the most severe type of asthma that can't be controlled with inhaled steroids.

"If this pans out, these asthmatics would have a different treatment option and be able to control their asthma without the side effects of steroids," he said. "They may actually be able to get off steroids completely or reduce the amount of steroids they take substantially."

More information

To learn more about asthma, visit the U.S. National Library of Medicine.

SOURCES: Ian Pavord, M.B., consultant physician, University Hospitals of Leicester NHS Trust, England; Rubin Cohen, M.D., director, Asthma Center, North Shore-LIJ Health System, New Hyde Park, N.Y.; Aug. 18, 2012, The Lancet, online

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug Suppresses Appetite in Mice: Study
2. Experimental Chemical Helps Blind Mice See
3. Experimental drug may extend therapeutic window for stroke
4. Fertility preservation with cryopreservation of ovarian tissue: from experimental to mainstream
5. Content Writing King Announces Cancellation Of Experimental Video Creation Process For Their Article Marketing Website
6. Experimental Vaccine Seems to Stop Nicotine Addiction in Mice
7. Experimental drug improves muscle strength among male cancer patients
8. Experimental Drug Helps Fight Some Childhood Cancers, Study Finds
9. Experimental Drug Eases Autistic Behaviors in Mice
10. Experimental Gel May Help Those With Advanced Parkinsons
11. Experimental Pill for Multiple Sclerosis Shows Promise
Post Your Comments:
Related Image:
Experimental Drug May Cut Severe Asthma Attacks: Study
(Date:10/10/2015)... ... October 10, 2015 , ... The Bank of America 500 NASCAR Sprint Cup ... Saturday, October 10th, defending race winner, Kevin Harvick, will battle it out for the ... and all of the stars of the NASCAR Sprint Cup Series. As part ...
(Date:10/10/2015)... ... October 10, 2015 , ... In the inaugural people’s choice contest, entitled Bold ... Work in Jacksonville, amongst medium-sized companies with 25 – 99 employees. The announcement was ... a celebratory gala on October 1st. , Many of the features of the ...
(Date:10/9/2015)... ... October 09, 2015 , ... With the FCPX LUT Vibrance pack ... footage. A LUT is a Lookup Table that contains a mathematical formula for modifying ... the table. This pack comes with 60 vibrant CUBE LUT files. , ...
(Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... ... now offering a special promotion on Invisalign, the orthodontic system that uses clear, ... The aligners are almost invisible against the teeth, which allow patients to complete ...
(Date:10/9/2015)... ... 09, 2015 , ... Confidence Plus Insurance has just celebrated ... initiative that involves working with a series of local charities throughout the California ... Insurance is the Gleason Park Electric Violin Ensemble (GPEVE). , GPEVE provides a ...
Breaking Medicine News(10 mins):
... , New Report Highlights Best and Worst State ... Va., Sept. 10 A new report by The Vision Council, ... for children entering school are inconsistent, impeding children,s ability to succeed ... visual processing of information, undetected vision problems can severely impact a ...
... largest network of Hispanic health advocates joins President Obama,s efforts to improve ... , WASHINGTON, Sept. 9 "There was a clear ... reform. We need to work together to get the job done and ... our history, it is essential that we do this to support America,s ...
... , Statement attributable to: J. James Rohack, M.D. President, ... that Medical Liability Reform is Needed , , ... is unacceptable. The AMA will continue to work for reform that makes ... opportunity this year to achieve meaningful health reform for America,s patients and ...
... Sept. 9 In commemoration of the first September 11 National ... Los Angeles will host three 2-hour volunteer orientations for 100+ youth and ... tour of the chapter,s new state of the art Emergency Operation Center, ... recent California wildfires. , , What: ...
... MECHANICSBURG, Pa., Sept. 9 Select Medical Holdings ... the launch of its initial public offering of 33,333,333 shares ... is expected to be between $11.00 and $13.00 ... of common shares by Select, and Goldman, Sachs & Co., ...
... 9 As the nation awaits President Obama,s address on ... Philanthropic Collaborative (TPC) sent today a letter to the President ... foundations in the field of health. , , ... the social and economic effectiveness of health-related philanthropic activities. ...
Cached Medicine News:
(Date:10/9/2015)... , Oct. 9, 2015  Impax Laboratories, Inc. ... will release its third quarter 2015 financial results on ... the U.S. financial markets. The Company will host a ... at 8:30 a.m., Eastern Time on November 9, 2015.  ... . --> The financial results and live ...
(Date:10/9/2015)... Eli Lilly and Company (NYSE: LLY ) ... 50 new jobs to its research and development presence at ... New York . --> ... include a translational immuno-oncology hub and a Lilly "portal," which ... to cutting-edge drug discovery capabilities, including chemistry and lead optimization ...
(Date:10/9/2015)... Switzerland , October 9, 2015   ... with KUR-111 meets primary efficacy endpoint San Diego, ... Orthopaedics and Chief of Orthopaedic Trauma, NYU Lutheran Medical Center, on ... San Diego, California , by Dr. Tom Lyon ... Medical Center, on 9 th October 2015 at 8:30a.m. PDT. ...
Breaking Medicine Technology:
... PDII ) today announced that Nancy Lurker, the company,s chief executive ... Services Conference at 8:30 am ET on February 7, 2012 at The ... webcast may be accessed under the "Investor Relations" tab on the company,s ... days. About PDI, Inc. PDI ...
... 2012  The IP & Science business of Thomson ... for Applied Economic Research (IPEA). This partnership provides ... Innovation, Regulation and Infrastructure (DISET) branch with access ... supplying them with generic pharmaceutical intelligence as well ...
Cached Medicine Technology:
CDIs new improved Implant Stabilizer has super-soft elastic bands with lace trim....
Bras and Breast Support...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test is ... Modified Albumin (IMA®) by measuring the cobalt ... serum sample. First identified in the early ... comes in contact with ischemic tissue in ...
Medicine Products: